Utah Medical Products, Inc.

Utah Medical Products, Inc.

UTMD
Utah Medical Products, Inc.US flagNASDAQ Global Select
65.53
USD
-1.29
- -
208.65MMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
10.73
10.94
10.65
10.43
11.14
11.29
12.55
11.58
13.42
14.41
13.84
12.26
11.89
11.71
Basic EPS, GAAP
3.02
3.01
3.14
3.22
2.29
4.99
3.94
2.96
4.05
4.54
4.58
4.16
3.48
3.38
Free Cash Flow per Basic Share
3.17
3.78
3.59
2.98
4.12
4.42
-1.2
5.29
5.65
5.61
6.14
4.45
4.53
4.12
Dividend per Share
0.97
1
1.02
1.04
0.79
1.08
1.1
1.13
3.14
0.87
1.18
1.28
1.23
1.23
Book Value per Share
15.18
17.2
19.33
21.53
23.04
26.93
29.66
30.47
31.56
34.74
38.12
38.78
39.72
40.64
Tangible Book Value per Share
3.31
5.67
8.14
9.95
12.42
16.26
15.23
17.75
20.6
24.95
30.21
30.28
32.21
33.09
Basic Weighted Avg Shares
4
4
4
4
4
4
4
4
4
4
4
3
3
3
Sales/Revenue/Turnover
40
41
40
39
41
42
47
42
49
52
50
41
39
38
Operating Margin (%)
36.62
39.25
38.97
41.19
45.9
44.52
37.59
32.5
38.49
37.85
33.4
33.23
29.6
29.99
Depreciation Expense
3
3
3
3
3
3
7
7
7
7
6
3
3
3
Net Income, GAAP
11
11
12
12
9
19
15
11
15
16
17
14
11
11
Effective Tax Rate (%)
21.21
28.04
23.81
26.15
55.43
4.65
17.65
21.98
22.42
20.26
17.19
17.43
20.01
19.24
Profit Margin (%)
28.17
27.56
29.49
30.86
20.54
44.18
31.4
25.6
30.15
31.51
33.12
33.92
29.3
28.91
Working Capital
17
21
29
31
44
56
51
58
69
84
102
93
95
97
LT Debt
5
1
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Total Equity
61
65
70
69
78
89
101
103
107
114
128
117
119
120
Return on Invested Capital (%)
17.14
16.33
16.66
16.92
11.34
21.07
15.14
10.43
13.9
14.18
11.39
9.11
7.72
7.64
Return on Capital (%)
18.22
17.02
16.67
15.75
10.2
19.97
13.93
9.7
13.03
13.61
12.55
10.34
8.73
8.38
Return on Common Equity (%)
21.35
18.62
17.19
15.75
10.2
19.97
13.96
9.73
13.07
13.65
12.58
10.36
8.75
8.39

Capital Structure

FRC

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
3
3
3
Market Capitalization
206
181
199

Working Capital

FRC

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
97
98
100
Cash, Cash Equivalents & STI
84
86
87
Accounts Receivable, Net
4
4
4
Inventories
8
8
9
Total Current Liabilities
3
3
4
Payables & Accruals
3
3
4
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
5.77%
3.25%
1.57%
Free Cash Flow
-64.99%
-3.84%
-0.94%
Net Income, GAAP
5.75%
2.81%
-18.65%
Sales/Revenue/Turnover
0.08%
-1.09%
-5.83%
Total Cash Common Dividend
15.03%
26.9%
-6.5%

Quarterly Revenue

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
11
10
10
9
41
2025
10
10
10
9
39
2026
9
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1.09
0.98
1.02
0.87
4.16
2025
0.92
0.94
0.82
0.81
3.48
2026
0.82
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.3
0.31
0.3
0.31
1.28
2025
0.31
0.31
0.31
0.31
1.23
2026
0.31
- -
- -
- -
- -

Company Description

APIChat
CEO
Kevin L. Cornwell
Full Time Employees
155
Sector
Healthcare
Industry
Medical - Instruments & Supplies
Address
7043 South 300 West Midvale UT United States of America 84047-1048
IPO Date
Mar 8, 1999
Business
Utah Medical Products, Inc. develops, manufactures, and distributes proprietary medical devices primarily for labor and delivery, neonatal intensive care, women's health, urology, surgery, and critical care. Its core product portfolio includes fetal monitoring accessories; vacuum-assisted delivery systems; labor and delivery tools; DISPOSA-HOOD infant respiratory hoods; DELTRAN PLUS blood pressure monitoring systems; Filshie Clip female surgical contraception devices; PATHFINDER PLUS endoscopic irrigation devices; suprapubic catheterization products; LIBERTY urinary incontinence treatment systems; ENDOCURETTE uterine endometrial tissue sampling curettes; and LUMIN uterine manipulation tools for laparoscopic procedures. The company targets hospitals, outpatient clinics, and physicians' offices globally. Founded in 1975 and headquartered in Salt Lake City, Utah, Utah Medical Products maintains a strong presence in the US medical device market and select international markets. In the last two years, the company has focused on strengthening its financial position amid sales fluctuations, notably reduced sales to a key OEM partner PendoTECH, while continuing to expand its product offerings with new devices like the CVX-Ripe cervical ripening catheter introduced to improve labor induction outcomes. Utah Medical Products also increased its quarterly dividend and appointed a new director in late 2024 and early 2025, reflecting a commitment to shareholder value and governance enhancements. It benefits from strong institutional ownership and has sustained share repurchase programs despite challenges from trade disruptions and rising operational costs.

Company News

APIChat
  • Utah Medical Products, Inc. Announces Quarterly Dividend

  • Utah Medical's Q1 Earnings Fall Y/Y Due to Elevated Litigation Costs

  • Utah Medical Products, Inc. Reports Financial Performance for First Quarter 2026

  • Head-To-Head Comparison: Utah Medical Products (NASDAQ:UTMD) and INLIF (NASDAQ:INLF)

  • Utah Medical Gains 32% in a Year: Should You Buy the Stock?

  • The Zacks Analyst Blog American Express, Intuitive Surgical, Shopify and Utah Medical Products

  • Utah Medical Products (NASDAQ:UTMD) Stock Passes Above 200 Day Moving Average – Here’s What Happened

  • Utah Medical's Q4 Earnings Hurt by OEM Decline, Fall Y/Y

  • Utah Medical Products, Inc. Announces Quarterly Dividend

  • UTMD Reports Year 2025 and Fourth Quarter Financial Performance

  • Utah Medical Products (NASDAQ:UTMD) Shares Cross Above Fifty Day Moving Average – Time to Sell?

  • Comparing Utah Medical Products (NASDAQ:UTMD) and Terumo (OTCMKTS:TRUMY)

  • Utah Medical Products (NASDAQ:UTMD) Stock Crosses Below 200 Day Moving Average – Here’s What Happened

  • Utah Medical Products, Inc. Appoints Director and Increases Quarterly Dividend

  • UTMD's Q3 Earnings Dip Y/Y on Trade Disruptions, Margins Squeeze

  • UTMD Reports Financial Performance for Third Calendar Quarter and Nine Months 2025

  • UTMD's Q2 Earnings Slip Y/Y Due to Falling OEM Sales, Stock Down 3%

  • Utah Medical Products, Inc. Announces Quarterly Dividend

  • Utah Medical Products Reports Q2 Decline

  • UTMD Reports Financial Performance for Second Calendar Quarter and First Half 2025